Thu. 21 Mar 2024, 2:07am ET
Benzinga
Earnings, News
Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.10) per share. This is a 87.2 percent increase over losses of $(0.75) per share from the same period last year. The company reported $66.35 million in sales this quarter. This is a 12.71 percent increase over sales of $58.87 million the same period last year.
Cash position of €102.3 million1 as of December 31, 2023 excluding the €15m from Sanofi, anticipated cash runway to end of 2025